Topic : Congresses and Events

Other Topics :

ASH 2016: A half-step may help on the road to TFR

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – In previous articles we’ve discussed the most recent information about treatment-free remission (TFR), in which people with a deep molecular response to treatment are able
Continue Reading →

ASH 2016: Stop trials – what if I lose my response?

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 2 Part 1 of this article summarized the results of recent Stop trials, which found that about 50% of people who try stopping their CML medication can remain in TFR (treatment
Continue Reading →

ASH 2016: Updated results from recent Stop trials

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 1 Part 2 Perhaps the hottest topic in CML research is whether people can stop taking their medication if they respond well to treatment for an extended period – what has been
Continue Reading →

ASH 2016: “Room for improvement” in CML monitoring, treatment

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – A new Canadian study has examined how often people with CML are tested to determine their response to medication (Hillis and colleagues. ASH 2016; abstract 3079). Informat
Continue Reading →

ASH 2016: Stem-cell transplantation: updated results

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – With the advent of tyrosine kinase inhibitor (TKI) therapies, stem-cell transplantation (SCT) is less commonly used to treat CML. While it does offer the potential of curi
Continue Reading →

ASH 2016: New treatment trials at ASH 2016

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – The annual meeting of the American Society of Hematology is the largest medical congress of the year, and featured the results of several new trials on chronic myelogenous
Continue Reading →

ASCO 2016: More trial results on stopping treatment

In recent years, the goal of treating CML has fundamentally shifted from controlling the disease process with a TKI medication (e.g. Gleevec, Tasigna, Sprycel, Bosulif) to something more ambitious: a suppression of CML that is so profound that treatment will no longer be needed. Preli
Continue Reading →

ASCO 2016: Why start with a more potent therapy?

Most people with CML start treatment with Gleevec, the first TKI that became available fifteen years ago. Another option, however, is to start with one of the more potent second-generation TKIs (e.g. Sprycel, Tasigna), which can achieve a more rapid control of the CML disease process.
Continue Reading →

ASCO 2016: Age not a barrier to stem cell transplants

The use of less aggressive drug regimens during stem cell transplantation has meant that more people – including the more elderly – may be eligible for the procedure. A U.S. study has now reported that older people don’t have a higher risk of complications compared to younger people (
Continue Reading →

ASCO 2016: What are the benefits of a “deep response”?

During treatment with a TKI (tyrosine kinase inhibitor), regular tests are needed to ensure that you’re responding to the medication. The amount of disease suppression is reported according to the reduction in leukemia proteins (or transcripts) compared to a reference. So a reduction
Continue Reading →